Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb…) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.
INSERM U970 PARCC (Paris Cardiovascular Research Center); Université Paris Descartes; Sorbonne Paris Cité; Paris, France ; Hôpital Européen Georges Pompidou; Service de Microbiologie; Paris, France.
Helene
H
Pere
Corinne
C
Tanchot
Jagadeesh
J
Bayry
Magali
M
Terme
Julien
J
Taieb
Cecile
C
Badoual
Olivier
O
Adotevi
Nathalie
N
Merillon
Elie
E
Marcheteau
Ve Ronique
VR
Quillien
Claire
C
Banissi
Alain
A
Carpentier
Federico
F
Sandoval
Mevyn
M
Nizard
Françoise
F
Quintin-Colonna
Guido
G
Kroemer
Wolf H
WH
Fridman
Laurence
L
Zitvogel
Ste Phane
SP
Oudard
Eric
E
Tartour